Atrial Flutter - Market Insights, Epidemiology, and Market Forecast - 2034
Description
Key Highlights
The report analyzes the existing treatment practices and unmet medical requirements in atrial flutter. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Atrial Flutter Overview
Atrial flutter is a prevalent form of supraventricular arrhythmia, originating from abnormal electrical activity in the atria—the heart’s upper chambers. It is characterized by a rapid yet regular atrial rhythm, typically resulting from a reentrant circuit within the right atrium. This arrhythmia arises due to disrupted or aberrant conduction pathways that lead to organized but excessively fast electrical impulses, impairing effective atrial contraction and potentially compromising hemodynamic stability.
Atrial flutter may be asymptomatic in some individuals, while others experience symptoms due to reduced cardiac efficiency. These can include shortness of breath, dizziness, fatigue, palpitations, rapid pulse, chest pain, lightheadedness, or syncope. Such manifestations result from the heart’s inability to maintain effective hemodynamics during rapid atrial contractions.
Atrial Flutter Diagnosis and Treatment Algorithm
Atrial flutter is diagnosed through a combination of clinical assessment and ECG confirmation. Common symptoms include palpitations, fatigue, and shortness of breath. A characteristic saw tooth pattern on ECG confirms the diagnosis. In intermittent cases, Holter monitoring or electrophysiological studies may be used.
Atrial flutter treatment targets both the arrhythmia and its underlying cause. Medications such as beta-blockers, calcium channel blockers, antiarrhythmics, and anticoagulants are commonly used to control rate, restore rhythm, and prevent stroke. When drugs are ineffective or not tolerated, cardioversion or catheter ablation may be employed. Device adjustments, like pacemaker or ICD reprogramming, can also help manage rhythm disturbances.
Atrial Flutter Epidemiology
The epidemiology section of the atrial flutter market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of atrial flutter. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
An analysis of US claims data from July 2004 to December 2005 revealed that 1.12% of patients had nontransient atrial flutter, and 2.2% presented with atrial flutter as their only documented arrhythmia.
Secondary research indicates that individuals aged 65 years and older account for approximately 73.0% of the global absolute prevalence of atrial fibrillation and atrial flutter (AF/AFL).
The total number of prevalent atrial fibrillation/atrial flutter cases increased by 67% from 1990 to 2021. Germany reported prevalence rates of over 1,000 cases per 100,000 people.
The epidemiology of atrial flutter is expected to change during the forecast period (2025–2034).
Atrial Flutter Market Outlook
The atrial flutter therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the atrial flutter market in the 7MM is expected to change significantly during the study period 2020–2034.
Atrial Flutter Drug Chapters
Marketed Atrial Flutter Drugs
RAPIBLYK/ONOACT (landiolol hydrochloride): AOP Orphan Pharmaceuticals /ONO PHARMACEUTICAL
RAPIBLYK is a highly selective beta-1-adrenoreceptor antagonist that counteracts the positive chronotropic effects of catecholamines—epinephrine and norepinephrine—on the heart, where beta-1 receptors are primarily concentrated. At the approved dosage, landiolol shows no membrane-stabilizing or intrinsic sympathomimetic activity in vitro. Clinically, RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
Following its availability in Europe and Japan, landiolol hydrochloride has now entered the US market. In November 2024, the US FDA approved RAPIBLYK for the rapid ventricular rate control in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter. Backed by data from five placebo-controlled trials, RAPIBLYK offers a rapid onset of action with minimal effect on blood pressure, positioning it as a valuable option for acute rate management.
Emerging Atrial Flutter Drugs
The acute pyelonephritis market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Anthos Therapeutics have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.
Abelacimab: Anthos Therapeutics
Abelacimab is a novel, fully human monoclonal antibody that binds Factor XI in its inactive state, delivering dual inhibition of Factor XI and XIa. By decoupling thrombosis from hemostasis, it represents a promising anticoagulation approach with a lower risk of bleeding.
Anthos Therapeutics has continued to advance its Factor XI inhibitor abelacimab with compelling data from the pivotal AZALEA-TIMI 71 study. First published in the New England Journal of Medicine (NEJM) in January 2025, following its late-breaking presentation at the 2023 American Heart Association (AHA) meeting, the study gained further momentum with two additional analyses presented at the American College of Cardiology Annual Scientific Session (ACC.25) in March 2025. These analyses reinforced abelacimab’s ability to significantly reduce bleeding risk across age groups and baseline bleeding profiles. Currently in Phase III development under the LILAC-TIMI 76 trial for stroke and systemic embolism prevention in atrial fibrillation, abelacimab is expected to reach study completion in the second half of 2026.
Atrial Flutter Market Segmentation
DelveInsight’s ‘Atrial Flutter – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future atrial flutter market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Atrial Flutter Market Size by Countries
The atrial flutter market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) atrial flutter market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Atrial Flutter Market Size by Therapies
Atrial Flutter Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034.
Atrial Flutter Drugs Uptake
This section focuses on the sales uptake of potential atrial flutter drugs that have recently been launched or are anticipated to be launched in the atrial flutter market between 2020 and 2034. It estimates the market penetration of atrial flutter drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the atrial flutter market.
The emerging atrial flutter therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the atrial flutter market.
Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Atrial Flutter.
Atrial Flutter Market Access and Reimbursement
DelveInsight’s ‘Atrial Flutter – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of atrial flutter.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current atrial flutter market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the atrial flutter domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or atrial flutter market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the atrial flutter unmet needs.
Atrial Flutter: KOL Insights
DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Harvard Medical School, US; German Heart Center Munich, Germany; Hôpital Européen Georges-Pompidou, France; San Raffaele Hospital, Italy; National Cerebral and Cardiovascular Center, Japan, and others.
“Atrial flutter is often difficult to diagnose due to its intermittent presentation and symptom overlap with other arrhythmias. ECG showing classic sawtooth flutter waves, especially in inferior leads, is key, but distinguishing it from other supraventricular tachycardias may require prolonged monitoring. Accurate diagnosis is critical to avoid mismanagement.”
“Modern atrial flutter management balances rhythm and rate control, tailored to symptoms, comorbidities, and stroke risk. Catheter ablation offers durable rhythm control, while antiarrhythmic and anticoagulant drugs remain vital, particularly for non-candidates of invasive therapy. Personalized, patient-centered approaches and shared decision-making are key to optimal outcomes.”
“Key unmet needs in atrial flutter management include earlier detection to prevent complications, improved risk stratification to guide treatment choices, and better strategies for long-term anticoagulation. The overlap with atrial fibrillation adds complexity, underscoring the need for further research to refine care and improve outcomes.”
Note: Detailed assessment of KOL Views will be provided in the full report on Atrial Flutter.
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the atrial flutter Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Atrial Flutter Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase I, Phase II and Phase III stages and examines companies involved in developing targeted therapeutics for atrial flutter. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging atrial flutter therapies.
Atrial Flutter Report Insights
1. What are the treatment goals for atrial flutter?
The primary goals of treating atrial flutter are to restore and maintain normal heart rhythm, control heart rate, relieve symptoms, prevent complications such as stroke or heart failure, and reduce the risk of recurrence through appropriate medical or interventional therapy and supportive care.
2. What are the challenges in managing atrial flutter?
Key challenges include risk of stroke, recurrence after treatment, difficulty in distinguishing it from atrial fibrillation, managing comorbid conditions, and determining the most suitable treatment approach—whether rate control, rhythm control, or catheter ablation.
3. What are the key factors driving the growth of the atrial flutter market?
The atrial flutter market is driven by increasing prevalence of atrial arrhythmias, growing awareness and diagnosis rates, advancements in catheter ablation and antiarrhythmic therapies, and an aging population prone to cardiovascular conditions.
4. How will the atrial flutter Market and Epidemiology Forecast Report benefit the clients?
The report will provide comprehensive insights into the current atrial flutter landscape, pipeline developments, competitive trends, clinical guidelines, and evolving patient needs, enabling informed decision-making, strategic planning, and identification of growth opportunities for stakeholders.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- The atrial flutter market is projected to grow steadily during the forecast period (2025–2034), driven by the rising adoption of safer anticoagulants and advancements in ablation technologies.
- The rising cases of atrial flutter are mainly due to the increasing prevalence of underlying risk factors such as hypertension, ischemic heart disease, heart failure, and structural heart abnormalities. Additionally, the aging population, improved diagnostic capabilities, and heightened clinical awareness have contributed to a greater identification of cases, further driving the apparent rise in atrial flutter prevalence.
- Atrial flutter treatment focuses on early rhythm or rate control, based on severity and risk factors. Stable cases may need oral drugs, while severe episodes often require cardioversion or ablation. Anticoagulation is standard, and poor response may suggest progression to atrial fibrillation.
- The current atrial flutter treatment landscape has limited competition, with few approved therapies such as RAPIBLYK/ONOACT (landiolol hydrochloride), among others.
- A key unmet need is the early identification of patients at high risk of progressing from atrial flutter to atrial fibrillation. Current tools lack precision in detecting underlying atrial disease, limiting proactive interventions. Improved risk stratification through biomarkers and atrial substrate mapping could enable more effective, personalized management and prevent long-term complications.
- The emerging pipeline for atrial flutter remains largely non-competitive, reflecting a significant gap in innovation. Among the few late-stage candidates, abelacimab shows strong potential to address this unmet need.
- Currently in Phase III under the LILAC-TIMI 76 trial for the prevention of stroke and systemic embolism in atrial fibrillation, abelacimab is anticipated to complete the study in the second half of 2026. Its advancement highlights a strategic push toward improving outcomes and broadening therapeutic options in a space with limited progress.
The report analyzes the existing treatment practices and unmet medical requirements in atrial flutter. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Atrial Flutter Overview
Atrial flutter is a prevalent form of supraventricular arrhythmia, originating from abnormal electrical activity in the atria—the heart’s upper chambers. It is characterized by a rapid yet regular atrial rhythm, typically resulting from a reentrant circuit within the right atrium. This arrhythmia arises due to disrupted or aberrant conduction pathways that lead to organized but excessively fast electrical impulses, impairing effective atrial contraction and potentially compromising hemodynamic stability.
Atrial flutter may be asymptomatic in some individuals, while others experience symptoms due to reduced cardiac efficiency. These can include shortness of breath, dizziness, fatigue, palpitations, rapid pulse, chest pain, lightheadedness, or syncope. Such manifestations result from the heart’s inability to maintain effective hemodynamics during rapid atrial contractions.
Atrial Flutter Diagnosis and Treatment Algorithm
Atrial flutter is diagnosed through a combination of clinical assessment and ECG confirmation. Common symptoms include palpitations, fatigue, and shortness of breath. A characteristic saw tooth pattern on ECG confirms the diagnosis. In intermittent cases, Holter monitoring or electrophysiological studies may be used.
Atrial flutter treatment targets both the arrhythmia and its underlying cause. Medications such as beta-blockers, calcium channel blockers, antiarrhythmics, and anticoagulants are commonly used to control rate, restore rhythm, and prevent stroke. When drugs are ineffective or not tolerated, cardioversion or catheter ablation may be employed. Device adjustments, like pacemaker or ICD reprogramming, can also help manage rhythm disturbances.
Atrial Flutter Epidemiology
The epidemiology section of the atrial flutter market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of atrial flutter. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
An analysis of US claims data from July 2004 to December 2005 revealed that 1.12% of patients had nontransient atrial flutter, and 2.2% presented with atrial flutter as their only documented arrhythmia.
Secondary research indicates that individuals aged 65 years and older account for approximately 73.0% of the global absolute prevalence of atrial fibrillation and atrial flutter (AF/AFL).
The total number of prevalent atrial fibrillation/atrial flutter cases increased by 67% from 1990 to 2021. Germany reported prevalence rates of over 1,000 cases per 100,000 people.
The epidemiology of atrial flutter is expected to change during the forecast period (2025–2034).
Atrial Flutter Market Outlook
The atrial flutter therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the atrial flutter market in the 7MM is expected to change significantly during the study period 2020–2034.
Atrial Flutter Drug Chapters
Marketed Atrial Flutter Drugs
RAPIBLYK/ONOACT (landiolol hydrochloride): AOP Orphan Pharmaceuticals /ONO PHARMACEUTICAL
RAPIBLYK is a highly selective beta-1-adrenoreceptor antagonist that counteracts the positive chronotropic effects of catecholamines—epinephrine and norepinephrine—on the heart, where beta-1 receptors are primarily concentrated. At the approved dosage, landiolol shows no membrane-stabilizing or intrinsic sympathomimetic activity in vitro. Clinically, RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
Following its availability in Europe and Japan, landiolol hydrochloride has now entered the US market. In November 2024, the US FDA approved RAPIBLYK for the rapid ventricular rate control in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter. Backed by data from five placebo-controlled trials, RAPIBLYK offers a rapid onset of action with minimal effect on blood pressure, positioning it as a valuable option for acute rate management.
Emerging Atrial Flutter Drugs
The acute pyelonephritis market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Anthos Therapeutics have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.
Abelacimab: Anthos Therapeutics
Abelacimab is a novel, fully human monoclonal antibody that binds Factor XI in its inactive state, delivering dual inhibition of Factor XI and XIa. By decoupling thrombosis from hemostasis, it represents a promising anticoagulation approach with a lower risk of bleeding.
Anthos Therapeutics has continued to advance its Factor XI inhibitor abelacimab with compelling data from the pivotal AZALEA-TIMI 71 study. First published in the New England Journal of Medicine (NEJM) in January 2025, following its late-breaking presentation at the 2023 American Heart Association (AHA) meeting, the study gained further momentum with two additional analyses presented at the American College of Cardiology Annual Scientific Session (ACC.25) in March 2025. These analyses reinforced abelacimab’s ability to significantly reduce bleeding risk across age groups and baseline bleeding profiles. Currently in Phase III development under the LILAC-TIMI 76 trial for stroke and systemic embolism prevention in atrial fibrillation, abelacimab is expected to reach study completion in the second half of 2026.
Atrial Flutter Market Segmentation
DelveInsight’s ‘Atrial Flutter – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future atrial flutter market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Atrial Flutter Market Size by Countries
The atrial flutter market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) atrial flutter market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Atrial Flutter Market Size by Therapies
Atrial Flutter Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034.
Atrial Flutter Drugs Uptake
This section focuses on the sales uptake of potential atrial flutter drugs that have recently been launched or are anticipated to be launched in the atrial flutter market between 2020 and 2034. It estimates the market penetration of atrial flutter drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the atrial flutter market.
The emerging atrial flutter therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the atrial flutter market.
Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Atrial Flutter.
Atrial Flutter Market Access and Reimbursement
DelveInsight’s ‘Atrial Flutter – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of atrial flutter.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current atrial flutter market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the atrial flutter domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or atrial flutter market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the atrial flutter unmet needs.
Atrial Flutter: KOL Insights
DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Harvard Medical School, US; German Heart Center Munich, Germany; Hôpital Européen Georges-Pompidou, France; San Raffaele Hospital, Italy; National Cerebral and Cardiovascular Center, Japan, and others.
“Atrial flutter is often difficult to diagnose due to its intermittent presentation and symptom overlap with other arrhythmias. ECG showing classic sawtooth flutter waves, especially in inferior leads, is key, but distinguishing it from other supraventricular tachycardias may require prolonged monitoring. Accurate diagnosis is critical to avoid mismanagement.”
“Modern atrial flutter management balances rhythm and rate control, tailored to symptoms, comorbidities, and stroke risk. Catheter ablation offers durable rhythm control, while antiarrhythmic and anticoagulant drugs remain vital, particularly for non-candidates of invasive therapy. Personalized, patient-centered approaches and shared decision-making are key to optimal outcomes.”
“Key unmet needs in atrial flutter management include earlier detection to prevent complications, improved risk stratification to guide treatment choices, and better strategies for long-term anticoagulation. The overlap with atrial fibrillation adds complexity, underscoring the need for further research to refine care and improve outcomes.”
Note: Detailed assessment of KOL Views will be provided in the full report on Atrial Flutter.
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the atrial flutter Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Atrial Flutter Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase I, Phase II and Phase III stages and examines companies involved in developing targeted therapeutics for atrial flutter. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging atrial flutter therapies.
Atrial Flutter Report Insights
- Atrial Flutter Patient Population
- Therapeutic Approaches
- Atrial Flutter Pipeline Analysis
- Atrial Flutter Market Size and Trends
- Atrial Flutter Market Opportunities
- Impact of Upcoming Therapies
- 10 Years Forecast
- The 7MM Coverage
- Atrial Flutter Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Atrial Flutter Market
- Atrial Flutter Drugs Uptake
- Atrial Flutter Current Treatment Practices
- Unmet Needs
- Atrial Flutter Pipeline Product Profiles
- Atrial Flutter Market Attractiveness
- How common is atrial flutter?
- What are the key findings of atrial flutter epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
- What are the currently available treatments for atrial flutter?
- What are the disease risk, burden, and unmet needs of atrial flutter?
- At what CAGR is the atrial flutter market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
- How would the unmet needs impact the atrial flutter market dynamics and subsequently influence the analysis of the related trends?
- What would be the forecasted patient pool of atrial flutter in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
- How many companies are currently developing therapies for the treatment of atrial flutter?
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the atrial flutter market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
1. What are the treatment goals for atrial flutter?
The primary goals of treating atrial flutter are to restore and maintain normal heart rhythm, control heart rate, relieve symptoms, prevent complications such as stroke or heart failure, and reduce the risk of recurrence through appropriate medical or interventional therapy and supportive care.
2. What are the challenges in managing atrial flutter?
Key challenges include risk of stroke, recurrence after treatment, difficulty in distinguishing it from atrial fibrillation, managing comorbid conditions, and determining the most suitable treatment approach—whether rate control, rhythm control, or catheter ablation.
3. What are the key factors driving the growth of the atrial flutter market?
The atrial flutter market is driven by increasing prevalence of atrial arrhythmias, growing awareness and diagnosis rates, advancements in catheter ablation and antiarrhythmic therapies, and an aging population prone to cardiovascular conditions.
4. How will the atrial flutter Market and Epidemiology Forecast Report benefit the clients?
The report will provide comprehensive insights into the current atrial flutter landscape, pipeline developments, competitive trends, clinical guidelines, and evolving patient needs, enabling informed decision-making, strategic planning, and identification of growth opportunities for stakeholders.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
200 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Market Overview at a Glance
- 3.1.. Market Share (%) Distribution in 2024
- 3.2.. Market Share (%) Distribution in 2034
- 4. Epidemiology and Market Methodology
- 5. Executive Summary
- 6. Key Events
- 7. Disease Background and Overview
- 7.1.. Introduction
- 7.2. Types
- 7.3.. Causes
- 7.4.. Pathophysiology
- 7.5.. Symptoms
- 7.6.. Risk Factor
- 7.7.. Diagnosis
- 7.7.1.. Diagnostic Algorithm
- 7.7.2.. Diagnostic Guidelines
- 7.8.. Treatment and Management
- 7.8.1.. Treatment Algorithm
- 7.8.2.. Treatment Guidelines
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale: The 7MM
- 8.2.1. Total Prevalent Cases of Atrial Flutter
- 8.2.2. Total Diagnosed Prevalent Cases of Atrial Flutter
- 8.2.3. Gender-specific Cases of Atrial Flutter
- 8.2.4. Treated Cases of Atrial Flutter
- 8.3. Total Prevalent Cases of Atrial Flutter in the 7MM
- 8.4. Total Diagnosed Prevalent Cases of Atrial Flutter in the 7MM
- 8.5.. The US
- 8.5.1. Total Prevalent Cases of Atrial Flutter
- 8.5.2. Total Diagnosed Prevalent Cases of Atrial Flutter
- 8.5.3. Treated Cases of Atrial Flutter
- 8.6.. EU4 and the UK
- 8.6.1. Total Prevalent Cases of Atrial Flutter
- 8.6.2. Total Diagnosed Prevalent Cases of Atrial Flutter
- 8.6.3. Treated Cases of Atrial Flutter
- 8.7.. Japan
- 8.7.1. Total Prevalent Cases of Atrial Flutter
- 8.7.2. Total Diagnosed Prevalent Cases of Atrial Flutter
- 8.7.3. Treated Cases of Atrial Flutter
- 9. Patient Journey
- 10. Marketed Therapies
- 10.1. RAPIBLYK/ONOACT (landiolol hydrochloride): AOP Orphan Pharmaceuticals /ONO PHARMACEUTICAL
- 10.1.1. Product Description
- 10.1.2. Regulatory Milestone
- 10.1.3. Other Development Activities
- 10.1.4. Clinical Trials Information
- 10.1.5. Safety and Efficacy
- The list will be continued in the report
- 11. Emerging Therapies
- 11.1. Abelacimab: Anthos Therapeutics
- 11.1.1. Drug Description
- 11.1.2. Other Development Activities
- 11.1.3. Clinical Trials Information
- 11.1.4. Safety and Efficacy
- 11.1.5. Analysts’ Views
- The list will be continued in the report
- 12. Atrial Flutter: Seven Major Market Analysis
- 12.1. Key Findings
- 12.2. Key Market Forecast Assumptions
- 12.2.1. Cost Assumptions and Rebates
- 12.2.2. Pricing Trends
- 12.2.3. Analogue Assessment
- 12.2.4. Launch Year and Therapy Uptake
- 12.3. Market Outlook
- 12.4. Attribute Analysis
- 12.5. Total Market Size of Atrial Flutter in the 7MM
- 12.6. Market Size of Atrial Flutter by Therapies in the 7MM
- 12.7. The US Market Size
- 12.7.1. Total Market Size of Atrial Flutter
- 12.7.2. Market Size of Atrial Flutter by Therapies
- 12.8. Market Size of Atrial Flutter in the EU4 and the UK
- 12.8.1. Total Market Size of Atrial Flutter
- 12.8.2. Market Size of Atrial Flutter by Therapies
- 12.9.. Japan Market Size
- 12.9.1. Total Market Size of Atrial Flutter
- 12.9.2. Market Size of Atrial Flutter by Therapies
- 13. Key Opinion Leaders’ Views
- 14. Unmet Needs
- 15. SWOT Analysis
- 16. Market Access and Reimbursement
- 16.1. The US
- 16.1.1. Centre for Medicare & Medicaid Services (CMS)
- 16.2. In EU4 and the UK
- 16.2.1. Germany
- 16.2.2. France
- 16.2.3. Italy
- 16.2.4. Spain
- 16.2.5. The UK
- 16.3. Japan
- 16.3.1. MHLW
- 17. Appendix
- 17.1. Abbreviations and Acronyms
- 17.2. Bibliography
- 17.3. Report Methodology
- 18. DelveInsight Capabilities
- 19. Disclaimer
- 20. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
